BTIG initiated coverage on Protagonist Therapeutics with a new price target
$PTGX
Biotechnology: Pharmaceutical Preparations
Health Care
BTIG initiated coverage of Protagonist Therapeutics with a rating of Buy and set a new price target of $55.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/17/2025 | $72.00 | Buy | Citigroup |
| 12/6/2024 | $47.00 | Neutral | Goldman |
| 12/6/2024 | $62.00 | Outperform | BMO Capital Markets |
| 11/5/2024 | $58.00 | Outperform | Wedbush |
| 9/24/2024 | $65.00 | Buy | TD Cowen |
| 9/9/2024 | $60.00 | Buy | Truist |
| 10/30/2023 | $32.00 | Overweight | CapitalOne |
| 5/25/2023 | $30.00 → $40.00 | Buy | Jefferies |
Rusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups, significantly reducing phlebotomy eligibility compared to placebo plus current standard of care, which was the primary endpoint All key secondary endpoints met with statistical significance, including a nearly three-fold reduction in the proportion of patients requiring phlebotomy and a four-fold improvement in hematocrit control in rusfertide arm compared to placebo arm, as well as improvements in patient-reported outcomes No serious adverse events considered related to rusfertide were reported Rusfertide has received Orphan Drug designation and Fast Track desig
− Study met the primary endpoint, with a significantly higher proportion of clinical responders on rusfertide compared to placebo − All four key secondary endpoints were met, including EU primary endpoint and patient-reported outcomes − Rusfertide was generally well tolerated; no new safety findings were observed in the study Protagonist Therapeutics, Inc. ("Protagonist") ((PTGX) and Takeda ((TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. The study met its primary endpoint and all fou
NEWARK, CALIFORNIA / ACCESSWIRE / January 6, 2025 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today reported that on January 2, 2025, it issued inducement awards to Newman Yeilding, M.D., upon his appointment to the role of Executive Vice President, Chief Scientific Officer, in accordance with the terms of his employment offer letter. Dr. Yeilding served in a consultant role as the Company's Chief Scientific Advisor from August 1, 2024 through January 1, 2025. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.Dr. Yeilding received options to purchase 38,520 sh
4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)
4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)
4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)